Heska (NASDAQ:HSKA) Now Covered by Piper Jaffray Companies

Piper Jaffray Companies initiated coverage on shares of Heska (NASDAQ:HSKA) in a research report sent to investors on Wednesday morning, BenzingaRatingsTable reports. The brokerage issued a neutral rating and a $68.00 price target on the medical research company’s stock.

Other analysts also recently issued reports about the stock. BidaskClub raised shares of Heska from a sell rating to a hold rating in a report on Wednesday. Guggenheim started coverage on shares of Heska in a report on Thursday, May 23rd. They set a neutral rating for the company. ValuEngine raised shares of Heska from a buy rating to a strong-buy rating in a report on Thursday, August 1st. Finally, Canaccord Genuity decreased their price objective on shares of Heska from $95.00 to $75.00 and set a buy rating for the company in a report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of $85.25.

HSKA stock opened at $72.77 on Wednesday. The company has a quick ratio of 2.05, a current ratio of 3.93 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $545.99 million, a price-to-earnings ratio of 51.25 and a beta of 1.07. Heska has a 12 month low of $62.47 and a 12 month high of $114.50. The firm has a 50 day moving average of $72.02 and a two-hundred day moving average of $77.39.



Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, August 6th. The medical research company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.04. The company had revenue of $28.15 million during the quarter, compared to the consensus estimate of $29.19 million. Heska had a net margin of 1.93% and a return on equity of 6.35%. On average, research analysts expect that Heska will post 0.04 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Financial Gravity Wealth Inc. bought a new stake in shares of Heska during the 2nd quarter worth $29,000. Manchester Capital Management LLC boosted its holdings in shares of Heska by 128.6% during the 1st quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock worth $34,000 after buying an additional 225 shares during the period. Aperio Group LLC bought a new stake in shares of Heska during the 2nd quarter worth $79,000. Quantamental Technologies LLC bought a new stake in shares of Heska during the 2nd quarter worth $120,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Heska by 47,400.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,425 shares of the medical research company’s stock worth $121,000 after buying an additional 1,422 shares during the period. 89.02% of the stock is owned by institutional investors and hedge funds.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Further Reading: Front-End Load

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.